Centrexion is a clinical-stage biopharmaceutical company developing novel, non-opioid therapies for chronic pain. The company advances mechanism-driven medicines designed to modulate specific pain signaling pathways, aiming to provide effective pain relief while avoiding the limitations of existing treatments.

Centrexion’s diversified pipeline spans multiple clinical-stage programs across distinct pain mechanisms and indications, reflecting the complexity of chronic pain. By applying deep insight into pain pathophysiology, the company seeks to deliver safer, more targeted treatment options that can meaningfully improve quality of life for patients living with chronic pain.